研究工具的可专利性探析——以美国法例为借镜被引量：6

Analysis on Patentability of Research Tools

导出

摘要研究工具是生物制药产业运营和发展的关键技术,需要利用专利制度予以保护。但素以保护范围宽泛而著称的美国专利法在实践中对研究工具可专利性的认识并不明确统一。这一方面是由于研究工具技术内容与自然法则、自然现象和抽象思想的密切关联,另一方面是由于申请研究工具专利常采用的具有"先占"效应的延展性权利要求所致。因此,对研究工具可专利性的探析需从可专利主题范围、授权实质要件和专利申请说明书诸项要件着手,以期为中国专利法在应对研究工具可专利性问题时提供些许借镜。 Being the key technologies of biopharmaceutical industry, research tools need to be protected by patent system. However, U.S. patent law does not reach a consensus about patentability of research tools in practice. On the one hand, it is because research tools are closely related with laws of nature, natural phenomena, and abstract ideas, on the other hand, it is because reach-through claims with ＂preempt＂ effect. Therefore, analysis of research tools patentability should start with patentable subject matter, permission conditions and patent specification in or- der to provide a reference for the China patent law.

作者周围

机构地区武汉大学知识产权法研究所

出处《法学评论》 CSSCI 北大核心 2014年第6期106-117,共12页 Law Review

基金教育部人文社会科学研究基金项目"‘世界专利制度’的发展及中国的应对"(项目编号:10YJA820077)的阶段性成果中央高校基本科研业务费专项资金(项目编号:2012106010209)资助

关键词研究工具可专利主题范围授权实质要件专利申请说明书 Research Tools Patentable Subject Matter Permission Conditions Patent Specification

分类号 D971.2 [政治法律—法学] D923.42 [政治法律—民商法学]

引文网络
相关文献

参考文献41

1NIH, Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomed- ical Research Resources : Final Notice, Fed. Reg., December 23, 1999, Vol. 64 72092, available at http ://www. ott.nih.gov/pdfs/ 64FR72090.pdf, last visited on June, 24,2013.
2Integra LifeSciences I Ltd. v. Merck KGaA, 331 F.3d 860, 872 n.4 (Fed. Cir. 2003).
3Federal Trade Commission, To Promote Innovation: The Proper Balance Of Competition And Patent Law And Policy (2003), p.18.
4U.S. Food and Drug Administration, Challenge And Opportunity On The Critical Path To New Medical Products, available at http://www.fda.gov/downloads/Drugs/SeieneeReseareh/ResearchAreas/uem079290.pdf,last visited on June, 26, 2013.
5Obama Administration, National Bioeconomy Blueprint, April 2012, p.1, available at http://www.whitehouse.gov/sites/de- fault/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.pdf,last visited on June, 26, 2013.
6generally Jeffrey Hanke, Genomics and New Technologies as Catalysts for Change in the Drug Discovery Paradigm, 25 J. L. Med. & Ethics 15 (2000).
7李其翔、张红.《新药药物靶标开发技术》,高等教育出版社2007年版,第3页.
8John P. Walsh, Ashish Arora & Wesley M. Cohen, Effects of Research Tool Patents and Licensing on Biomedical Innova- tion, in Patents In The Knowledge- Based Economy, 285-340, Wesley M. Cohen & Stephen A. MerriU eds. 2003.
9何志煌.《生技产业的竞争与价值》,载《生物产业》2004年第1期.
10Case Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).